Clinical Trials to Treat Adult Metastatic Brain Tumors

Trials 1-25 of 68
1 2 3 Next >

  • Cisplatin with or without Veliparib in Treating Patients with Recurrent or Metastatic Triple-Negative and / or BRCA Mutation-Associated Breast Cancer with or without Brain Metastases

    This randomized phase II trial studies how well cisplatin works with or without veliparib in treating patients with triple-negative breast cancer and / or BRCA mutation-associated breast cancer that has come back or has or has not spread to the brain. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known if cisplatin is more effective with or without veliparib in treating patients with triple-negative and / or BRCA mutation-associated breast cancer.
    Location: 749 locations

  • Whole-Brain Radiation Therapy or Stereotactic Radiosurgery with or without Lapatinib Ditosylate in Treating Patients with Brain Metastasis from HER2-Positive Breast Cancer

    This randomized phase II trial studies how well whole-brain radiation therapy or stereotactic radiosurgery with or without lapatinib ditosylate works in treating patients with breast cancer that has too many of a protein called human epidermal growth factor receptor 2 (HER2) on its cells and has spread to the brain. Radiation therapy uses high energy x rays to kill tumor cells and shrink tumors. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether whole-brain radiation therapy or stereotactic radiosurgery together with lapatinib ditosylate is an effective treatment for brain metastasis from breast cancer.
    Location: 211 locations

  • Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)

    The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1-10 brain metastases, treated with NovoTTF-100M compared to supportive treatment alone. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.
    Location: 23 locations

  • A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

    This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine in either the adjuvant or metastatic setting (prior anthracycline may be omitted if medically appropriate or contraindicated for the patient).
    Location: 13 locations

  • Osimertinib with or without Bevacizumab in Treating Patients with EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

    This phase II trial studies how well osimertinib with or without bevacizumab works in treating patients with EGFR positive non-small cell lung cancer that has spread to the brain. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as bevacizumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with or without bevacizumab may work better in treating patients with non-small cell lung cancer.
    Location: 10 locations

  • Phase 1 / 2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers

    This is a Phase 1 / 2, multi-center, open-label study designed to evaluate the safety and efficacy of LOXO-195 when administered orally to patients age ≥ 1 month and older with NTRK fusion cancers treated with a prior TRK inhibitor.
    Location: 12 locations

  • VX-970 and Whole Brain Radiation Therapy in Treating Patients with Brain Metastases from Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors

    This phase I trial studies the side effects and best dose of ATR kinase inhibitor M6620 (VX-970) when given together with whole brain radiation therapy in treating patients with non-small cell lung cancer, small cell lung cancer, or neuroendocrine tumors that have spread from the original (primary) tumor to the brain. ATR kinase inhibitor M6620 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving ATR kinase inhibitor M6620 together with radiation therapy may be a better treatment for non-small cell lung cancer, small cell lung cancer, or neuroendocrine tumors.
    Location: 8 locations

  • A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

    This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed and eliminated) of ascending doses of AZD1390 in combination with distinct regimens of radiation therapy.
    Location: 7 locations

  • Sorafenib Tosylate and Whole Brain Radiation Therapy in Treating Patients with Brain Metastases from Breast Cancer

    This phase I trial studies the side effects and best dose of sorafenib tosylate when given together with whole brain radiation therapy in treating patients with breast cancer that has spread to the brain. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving sorafenib tosylate and whole-brain radiation therapy together may kill more tumor cells.
    Location: 6 locations

  • Whole-Brain Radiotherapy or Stereotactic Radiosurgery in Treating Patients with 5-20 Metastatic Malignant Tumors in the Brain

    This randomized phase III trial studies how well whole-brain radiotherapy or stereotactic radiosurgery works in treating patients with 5-20 malignant tumors that have spread to the brain from other parts of the body. Whole-brain radiotherapy delivers radiation to the entire brain Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. It is not yet known whether whole-brain radiotherapy or stereotactic radiosurgery works better in treating patients with 5-20 malignant tumors in the brain.
    Location: 5 locations

  • Pembrolizumab with or without Stereotactic Radiosurgery in Treating Patients with Central Nervous System Metastases

    This phase II trial studies how well pembrolizumab with or without stereotactic radiosurgery works in treating patients with cancer that has spread to the central nervous system. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Giving pembrolizumab and stereotactic radiosurgery may work better in treating patients with cancer that has spread to the central nervous system.
    Location: 4 locations

  • Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

    This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung cancer.
    Location: 3 locations

  • Pembrolizumab and Stereotactic Radiosurgery in Treating Patients with Melanoma or Non-small Cell Lung Cancer That Has Spread to the Brain

    This pilot trial studies the side effects of giving pembrolizumab together with stereotactic radiosurgery to treat patients with melanoma or non-small cell lung cancer that has spread to the brain. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Giving pembrolizumab together with stereotactic radiosurgery may be a better treatment for patients with melanoma or non-small cell lung cancer that has spread to the brain.
    Location: 3 locations

  • Palbociclib in Treating Patients with Metastatic HER-2 Positive Breast Cancer with Brain Metastasis

    The purpose of this study is to evaluate if the study drug palbociclib has anti-tumor activity against the breast cancer that has spread to the brain and also to determine the overall radiographic response rate in the central nervous system (CNS). Palbociclib is an anti-cancer medication that has been shown to stop cancer cells from growing. It has been approved in hormone positive breast cancer, along with other hormone therapies and has been found to be effective. The preclinical studies suggest that the drug may also have activity in other types of breast cancer, such as human epidermal growth factor receptor 2 (HER2) positive breast cancer. The purpose of this study is to see if the study drug is effective in patients with brain metastasis, who have HER2-positive breast cancer.
    Location: 3 locations

  • Atezolizumab and Stereotactic Radiation in Treating Participants with Stage IV Triple Negative Breast Cancer and Brain Metastasis

    This phase II trial studies how well atezolizumab and stereotactic radiosurgery work in treating participants with stage IV triple negative breast cancer that has spread to the brain. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic radiation is a specialized radiation therapy that uses many precisely focused radiation beams to treat tumors with minimal impact on the surrounding healthy tissue. Giving atezolizumab and stereotactic radiation may work better in treating participant with triple negative breast cancer.
    Location: 2 locations

  • Atezolizumab, Pertuzumab, and High-Dose Trastuzumab in Treating Participants with Her2-Positive Breast Cancer with Central Nervous System Metastases

    This phase II trial studies how well atezolizumab works when given together with pertuzumab and high-dose trastuzumab in treating participants with HER2-positive breast cancer that have spread to the central nervous system from other parts of the body. Immunotherapy with monoclonal antibodies, such as atezolizumab, pertuzumab and trastuzumab, may help the body’s immune system attack the cancer, may induce changes in body’s immune system, and may interfere with the ability of tumor cells to grow and spread.
    Location: 2 locations

  • Stereotactic Radiosurgery in Treating Participants with Small Cell Lung Cancer and 1-6 Brain Metastases

    This phase II trial studies how well stereotactic radiosurgery works in treating participants with small cell lung cancer and 1-6 tumors that have spread to the brain from other parts of the body. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.
    Location: 3 locations

  • A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and / or to Leptomeninges

    This is a phase II, multi-center, open-label, five-arm study in which the efficacy and safety of oral ceritinib treatment will be assessed in patients with NSCLC metastatic to the brain and / or to leptomeninges harboring a confirmed ALK rearrangement, using the FDA approved Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular Inc.) test and scoring algorithm (including positivity criteria). If documentation of ALK rearrangement as described above is not locally available, a test to confirm ALK rearrangement must be performed by a Novartis designated central laboratory. Patients must wait for the central laboratory result of the ALK rearrangement status before initiating treatment with ceritinib.
    Location: 2 locations

  • PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients with Stage II-IV Non-small Cell Lung Cancer

    This phase II trial studies how well intensity modulated radiation therapy adjusted by positron emission tomography (PET) scanning together with combination chemotherapy works in treating patients with stage II-IV non-small cell lung cancer (NSCLC). Radiation therapy uses high energy x rays to kill tumor cells. In intensity-modulated radiotherapy, multiple beam angles and dozens of beam segments are used to deliver highly conformal radiation therapy. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving PET-adjusted IMRT together with combination chemotherapy may kill more tumor cells.
    Location: 2 locations

  • Tumor Infiltrating Lymphocytes, Aldesleukin, and Pembrolizumab after Chemotherapy in Treating Patients with Metastatic Cancers

    This phase II trial studies how well tumor infiltrating lymphocytes, aldesleukin, and pembrolizumab work after chemotherapy in treating patients with cancers that has spread to other parts of the body (metastatic). Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Aldesleukin may stimulate lymphocytes to kill tumor cells. Treating lymphocytes with aldesleukin in the laboratory may help the lymphocytes kill more tumor cells when they are put back in the body after chemotherapy.
    Location: 2 locations

  • HER2-CAR T cells in Treating Patients with Brain or Leptomeningeal Metastases

    This phase I trial studies the side effects and best dose of HER2-CAR T cells in treating patients with cancer that has spread to the brain or leptomeninges. HER2-CAR T cells delivered into the ventricles of the brain may recognize and kill tumor cells.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • Stereotactic Radiosurgery in Treating Participants with Brain Metastases and Studying Their Neurocognitive Decline

    This phase I / II trial studies the best dose and side effects of stereotactic radiosurgery intreating participants whose cancer cells have spread to the brain from other organs in the body and studying their neurocognitive decline. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas

  • Stereotactic Radiosurgery followed by Tumor Treating Fields Therapy in Treating Participants with Small Cell Lung Cancer with Brain Metastases

    This trial studies how well stereotactic radiotherapy followed by tumor treating fields therapy work in treating participants with small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Given stereotactic radiosurgery and tumor treating fields therapy may help to reduce the chances of cancers coming back in other parts of your brain that are not being treated with stereotactic radiosurgery.
    Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

  • Transduced Peripheral Blood Lymphocytes in treating Participants with Metastatic Tumors

    This phase II trial studies how well autologous peripheral blood lymphocytes (PBLs) retrovirally-transduced with T cell receptors (TCRs) targeting neoantigens work in treating participants with tumors that have spread to the other places in the body. White blood cells (lymphocytes) taken from participants tumors are treated and grown in the laboratory to recognize specific mutations and attack only tumor cells with those mutations. This may improve the body's ability to fight the cancer.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Stereotactic Radiosurgery before Resection in Treating Participants with Solid Tumor Brain Metastases

    This phase II trial studies how well stereotactic radiosurgery before resection works in treating participants with solid tumors that have spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Performing stereotactic radiosurgery before surgery may sterilize the cancer cells surrounding the brain tumor so they may not spread during surgery.
    Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana


1 2 3 Next >